NeuroVive Pharmaceutical AB Interim Report January – September 2016
New business model generates opportunities
Press releases
NeuroVive’s recruitment of Michele Tavecchio strengthens its research organization
Lund, Sweden, November 8, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the company has recruited Michele Tavecchio ...
NeuroVive reports positive pre-clinical results in NASH
Lund, Sweden, November 1, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced positive pre-clinical results with one of its cy ...
NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee
Lund, Sweden, October 26, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the Annual General Meeting of NeuroVive Pha ...
NeuroVive completes closure of Lyon subsidiary
Lund, Sweden, October 25, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has completed the closure of its dormant ...
NeuroVive and Arbutus sign termination agreement
Lund, Sweden, October 21, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the license agreement with Arbutus Biopharm ...
NeuroVive discontinues development of CicloMulsion for acute kidney injury
Lund, Sweden, October 13, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced results from the exploratory clinical phase II s ...
NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Lund, Sweden, September 7, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the company is scheduled to present at the ...
NeuroVive announces that the clinical study CiPRICS will be presented at the Swedish Thorax meeting in October 2016
Lund, Sweden, August 30, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the clinical study CiPRICS will be presented ...
NeuroVive’s Chief Operating Officer Jan Nilsson leaves the company
Lund, Sweden, August 24, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that its Chief Operating Officer, Jan Nilsson lea ...
NeuroVive Pharmaceutical – Interim report January-June 2016
Business operations
NeuroVive completes 10 percent acquisition of Isomerase Therapeutics
Lund, Sweden, August 15, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the second step in the previously announced ...